Avoiding The Potholes Along The Pathway To Commercial Cell Therapies

The emergence of commercially available cell therapies has been, and continues to be, an inflection point for the cell therapy industry. An initial pathway from process development to commercial manufacture has been described, yet many challenges remain along the way.

Invetech hosted a panel discussion during the recent International Society Cell & Gene Therapy (ISCT) conference in Melbourne, Australia to explore the main challenges along the pathway from process development to commercial cell therapies.

The panel, chaired by Invetech’s Jon Ellis, and comprising of Dr. Dawn Driscoll (Cell Therapies Pty Ltd), Dr. Joanne Kurtzberg (Duke University) and Dr. Wen Bo Wang (Fate Therapeutics) had an insightful discussion on the role that considered automation plays in navigating three of the biggest potholes in commercial cell therapies:

• Productivity of human resources
• Consistency of manufacturing
• Access to capital